Russia completes clinical trials of second potential COVID-19 vaccine - RIA

FILE PHOTO: A woman holds a small bottle labeled with a "Vaccine COVID-19" sticker and a medical syringe in this illustration taken April 10, 2020. REUTERS/Dado Ruvic/Illustration//File Photo

MOSCOW (Reuters) - Russia has completed clinical trials of a second potential vaccine against COVID-19, developed by Siberia's Vector Institute, the RIA news agency cited Russian consumer safety watchdog Rospotrebnadzor as saying on Wednesday.

The institute completed early-stage human trials, known as Phase II, earlier this month.